Navigation Links
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Date:11/15/2011

AMSTERDAM, November 16, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan designation in the European Union provides several benefits including 10 years of market exclusivity from product launch and access to the central authorization procedure.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"Orphan designation is an important milestone for our hemophilia B gene therapy program and will provide additional support to our negotiations as we seek potential licensing partners," said Jörn Aldag, CEO of AMT. "A successful gene therapy for hemophilia could dramatically change not only the lives of patients but also the current hemophilia market that is dominated by protein replacement therapies."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to desi
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
2. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
3. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
6. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
7. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today ... trial of,KW-3902, an adenosine A1 receptor antagonist in ... heart failure (CHF),that indicate a strong trend toward ... KW-3902 experienced a higher rate of,improvement in dyspnea, ...
... Results Presented at the 12th Congress of ... 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... EHA in Vienna, Austria, showed positive responses ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
(Date:11/27/2014)... November 27, 2014 “LAB.C” was featured on ... the latest and coolest technology products available to consumers. Mallory ... product review and shared with viewers the company ... and Android devices. , Consumers love portability and functionality. ... Cable Case for the iPhone5 and 5S has a portable ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... Marietta, GA (PRWEB) November 27, 2014 "The ... the whole month of December is full of laughter as ... Tandy Wilson won by making a sweater from scratch. " ... lit Christmas tree, and if that weren't ridiculous enough, the ... on top. , For those interested in participating this ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 Ethane ... has announced it will provide a 10% Christmas discount on ... month of December. The discount offer will begin on 1 ... 2014. , About this offer, a PPC professional working ... for all, especially for small businesses, as this big discount ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... problem drinkers using alcohol to cope with personal problems ... drinking into adulthood, a recent study suggests. , The ... are still high-risk drinkers by age 34 may have ... development that typically occurs during college, including the ability ...
... 24 Conseco, Inc. (NYSE: CNO ) ... existing $911.8 million senior secured credit agreement. Banc ... in connection with the amendment. The amendment, which ... in the current repayment schedule, is expected to provide ...
... "Hangin, Out With My Baby," ... with their newborns, infants and toddlers, will be distributed free ... hospitals throughout the U.S. Starting today with a live concert ... CDs will be given away this year by participating hospitals.Arranged ...
... Cancer Society Cancer Action Network, the American Heart Association, ... Kids applaud Senator Frank Lautenberg of New Jersey,s call ... authority and immediately remove e-cigarettes from the market. ... publications during the past few weeks saying that e-cigarettes ...
... help metropolitan public health agencies,prepare to deliver essential ... or natural disease outbreak has succeeded in improving,the ... Corporation study. , Researchers found that the federal ... areas, appears to have improved,agencies, ability to rapidly ...
... experts at The University of Nottingham have shown that ... the quality of life for many community-based dialysis patients. ... journal Biomaterials , have shown that the catheter ... wider variety of pathogens and protect Continuous Ambulatory Peritoneal ...
Cached Medicine News:Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
... general-purpose agarose, like the entire line of ... grade. This ensures that DNA recovered from ... compromising quality. Certified molecular biology agarose is ... molecular weight, resulting in a gel structure ...
Medicine Products: